Image

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

Recruiting
18 years and older
All
Phase 1

Powered by AI

Overview

Customers/gamblers gambling at Norsk Rikstoto (gambling monopolist in Norway providing horse gambling products with potential gambling problems will be randomly allocated to receive a proactive phone call (encouraging them to change their gambling behavior - e.g., be lowering the loss limit) or to a control condition. Outcomes will be short and long terms registered gambling behavior.

Description

Norsk Rikstoto (gambling monopolist in Norway providing horse gambling products) enforces registered play, hence all gambling transactions and outcomes of stakes of all customers are registered and stored for 5 years. Based on daily algorithms high risk gamblers are identified. Gamblers 18-50 years who for at least 5 of the last 30 days have been identified as high risk gamblers will according to a 1.5:1 ratio be allocated to a proactive call condition or to a control condition.

The call will be based on principles from motivating interviewing and will contain encouragements to alter gambling behavior (e.g., lowering loss limits). Primary outcome comprises theoretical loss (total bet x house advantage ((100% - payback%) / 100)). Secondary outcomes comprises total stakes made by the customer and loss percentage (proportion of stake that is lost). Baseline data comprises gambling behavior the 30 days before the call. Short-term effects comprise cumulative registered gambling behavior the first 90 days after the call whereas long-term effects consist of cumulative registered gambling behavior day 91-180 after the call. A random block design will be used where 15 eligible customers each week will be allocated either to the proactive call condition (n=9) or to the control condition (n=6).

Eligibility

Inclusion Criteria:

  • Being identified (based on an algorithm used by Norsk Rikstoto/the gambling provider) as a high risk gambler at least 5 of the last 30 days

Exclusion Criteria:

  • Previously received a proactive call from Norsk Rikstoto

Study details
    Acute Lymphoblastic Leukemia

NCT07066397

TriArm Therapeutics (Taiwan) Limited

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.